An ultrahigh-throughput screening assay for estrogen receptor ligands

Analytical Biochemistry

Volumn 275, Issue 2, 1999, Pages 243-247

  Allan, George F ^a   Hutchins, Amy ^a   Clancy, Joanna ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Estrogen; High throughput; Nuclear receptor; Robot; Screen

Indexed keywords

ANTIBODIES; COMPLEXATION; MAMMALS; RADIOACTIVITY; ROBOTS; SCREENING; STEROID HORMONES; TRANSCRIPTION FACTORS;

ESTROGEN; HIGH THROUGHPUT; IMMOBILIZED RECEPTORS; NUCLEAR RECEPTORS; PHARMACEUTICAL INDUSTRY; RECEPTOR-LIGAND COMPLEX; THROUGHPUT SCREENING; THYROID HORMONE RECEPTOR;

LIGANDS;

ESTROGEN RECEPTOR; LIGAND;

ANALYTIC METHOD; ARTICLE; COMPLEX FORMATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; REPRODUCIBILITY; SCINTILLATION;

MAMMALIA;

EID: 0033571579     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1006/abio.1999.4335     Document Type: Article

References (10)

1. Tsai M.-J., O'Malley B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
2. Cook N. D. Scintillation proximity assay: A versatile high-throughput screening technology. Drug Discovery Today. 1:1996;287-294.
3. Picardo M., Hughes K. T. Devlin J. P. High Throughput Screening. 1997;307-316 Dekker, New York.
4. 3H]estradiol binding constants for hER-HBD. BioTechniques. 18:1995;146-151.
5. Haggblad J., Carlsson B., Kivela P., Siitari H. Scintillating microtitration plates, a platform for hormone and DNA binding assays. Model experiments with the human estrogen receptor. Lab. Auto. Inf. Man. 31:1996;195-201.
6. Nelson J. S., Parks D. J., Consler T. G., Blanchard S. G. Development of scintillation proximity assay for peroxisome proliferator-activated receptor γ ligand binding domain. Anal. Biochem. 257:1998;112-119.
7. Elbrecht A., Chen Y., Adams A., Berger J., Griffin P., Klatt T., Zhang B., Menke J., Zhou G., Smith R. G., Moller D. E. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ. The role of Cys313 in ligand binding. J. Biol. Chem. 274:1999;7913-7922.
8. Janowski B. A., Grogan M. J., Jones S. A., Wisely G. B., Kliewer S. A., Corey E. J., Mangelsdorf D. J. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ Proc. Natl. Acad. Sci. USA. 96:1999;266-271.
9. Korach K. S., Migliaccio S., Davis V. L. Munson P. L. Principles of Pharmacology. Basic Concepts and Clinical Applications. 1995;809-825 Chapman and Hall, New York.
10. Kuiper G. G. J. M., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.-A. Comparison of the ligand binding specificity and transcript distribution of estrogen receptors α and β Endocrinology. 183:1997;863-870.